Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

BACKGROUND: 131-iodine ((131)I) administration after surgery remains a standard practice in differentiated thyroid cancer (DTC). In 2014, the American Thyroid Association presented new guidelines for the staging and management of DTC, including no systematic (131)I in patients at low-risk of recurre...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Thyroid Res
Huvudupphovsmän: Iconaru, Laura, Baleanu, Felicia, Taujan, Georgiana, Duttmann, Ruth, Spinato, Linda, Karmali, Rafik, Bergmann, Pierre, Hambye, Anne-Sophie
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2020
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7488699/
https://ncbi.nlm.nih.gov/pubmed/32944083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13044-020-00089-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk